SUTRO BIOPHARMA, INC. (STRO) stock intrinsic value fair value estimate & owner earnings analysis

Sutro Biopharma is a clinical-stage cancer-drug developer. It designs antibody-drug conjugates, which are antibodies that carry a toxic payload to tumor cells. Its revenue is not from selling medicines. It comes from licensing and collaboration payments from partners: Astellas ($45.4M in 2025), Ipsen ($56.4M), Vaxcyte, and small amounts from Tasly and Merck. Revenue of $102.5M in 2025 looks strong, but $53.2M of it was Ipsen deferred revenue recognized in a single year when the STRO-003 agreement was wound down. That is a one-time recognition, not a run rate. In the first half of 2026, revenue was only $24.4M, against $81.1M in the first half of 2025. The business has not produced owner earnings in the way we measure them (operating cash flow, less working-capital swings, less stock compensation, less maintenance capital spending). Operating cash flow was negative in 2017, 2019, 2020, 2021, 2023, 2024 and 2025. The only positive years were 2018 (+$12.7M) and 2022 (+$3.5M), both driven by partner upfront payments rather than a self-funding business. Operating cash flow was -$191.5M in 2024, -$177.2M in 2025 and -$80.5M in the first six months of 2026. Stock compensation is a further real cost of roughly $14M to $25M a year. Cumulative losses total about $978M. Nothing that can be named and evidenced today supports positive future owner earnings. No product is approved or has a revenue stream secured by contract. Partner milestone payments, such as the $7.5M Astellas payments earned in 2025, are contingent on programs advancing, so they are not counted. Future Vaxcyte royalties were sold to Blackstone in June 2023, so that royalty income no longer belongs to Sutro shareholders, and the $219.5M liability on the balance sheet for that sale is a non-cash obligation. In 2025, the company deprioritized its luvelta program, and restructuring costs were $53.4M. Bear case ($0 per share): the company keeps spending more than it collects, the current cash and investments are used up in research and wind-down costs, and no partnered program produces a lasting stream. Stockholders' equity was already negative at -$103.3M at June 30, 2026. Base case ($0 per share): the same path with partner payments covering only part of the research budget. With no earnings stream we can evidence, this case is worth nothing to today's shareholders. Any value would come from unproven drug results, which we do not credit. Bull case (about $0.25 per share): cash and marketable securities were $165.2M at June 30, 2026, after a $110M share sale in February 2026 at $13.98 a share. Operating cash burn is running at about $161M a year (first-half figure doubled). Under that pace, the cash left after one year is about $4.1M, or roughly $0.25 per share on 16.6M shares. This is a cash-runway figure, not a discounted earnings valuation. The case assumes no further dilution and no lasting earnings, only that what is left is worth its face amount. We have not credited pipeline success, since that has not yet happened. What would make this analysis wrong: a partner program, such as those with Astellas, reaching a large approval or milestone stage that produces durable cash flow; or a sharp cut in spending that brings the company near break-even. Neither is visible in the filings. The company also has a history of raising money by selling shares (April 2024 at $51.80, February 2026 at $13.98, both adjusted for the December 2025 reverse split), which dilutes existing owners. On listing, the stock fell below Nasdaq's $1.00 minimum bid in June 2025 and regained compliance in December 2025 through a reverse stock split. The 10-K filed in March 2026 states that cash is sufficient to fund operations for at least 12 months. At the first-half 2026 burn rate, the remaining cash would last only about a year from mid-2026, so more financing or a deeper cost cut looks likely.